MDGL250117C125000
- 217.39
- +49.27+29.31%
Madrigal Pharmaceuticals Newsroom
Madrigal Pharmaceuticals Analyst Ratings
Madrigal Pharmaceuticals' Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $427
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Announces Target Price $155
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Madrigal Pharmaceuticals Price Target Raised to $427 From $415 at JMP Securities
Insider Sale: Director at $MDGL (MDGL) Sells 520 Shares
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Path To Profitability
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Express News | Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 3.23 Million in Common Stocks
Top 3 Health Care Stocks That May Dip This Month
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400